Evidence map›Paper›PMID 29019175›Full record

Trial reportAnnals of surgical oncology2017

Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions.

Cristina O'Donoghue, Matthew C Perez, John E Mullinax, Danielle Hardman, Sean Sileno, Syeda Mahrukh Hussnain Naqvi, Youngchul Kim, Ricardo J Gonzalez, Jonathan S Zager

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Diagnosis and Management of Cutaneous Metastases from Melanoma.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Management of In-Transit Metastases.Current oncology reports · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Cristina O'DonoghueDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Matthew C PerezDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
John E MullinaxDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Danielle HardmanMorsani College of Medicine, University of South Florida, Tampa, FL, USA.
Sean SilenoMorsani College of Medicine, University of South Florida, Tampa, FL, USA.
Syeda Mahrukh Hussnain NaqviDepartment of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA.
Youngchul KimDepartment of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA.
Ricardo J GonzalezDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. Jonathan.zager@moffitt.org.
Moffitt Cancer Center · USUniversity of South Florida · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

backgroundIsolated limb infusion (ILI) is a minimally invasive technique for delivering regional chemotherapy to an extremity for patients with locally advanced cutaneous malignancies and sarcoma.

methodsA single-institution, prospectively collected database was analyzed for intention-to-treat with ILI.

resultsFrom 2007 to 2016, 163 patients underwent 205 procedures (201 were successfully completed), and four malignancies were treated: melanoma (72.1% of all ILIs), sarcoma (23.4%), squamous cell carcinoma (SCC; 2.0%) and Merkel cell carcinoma (MCC; 2.5%). A median grade II regional Wieberdink toxicity score was observed, with 88.1% of patients experiencing grade II or less. Median follow-up was 21.8 months, and overall response rate (ORR) was 59.0% for melanoma, 48.9% for sarcoma, 50.0% for SCC, and 60.0% for MCC. A significant difference (p = 0.04) between upper (76.9%) and lower extremity (55.1%) ORR was observed in patients with melanoma. When comparing responders with nonresponders, patients with melanoma had significantly longer in-field progression-free survival (IPFS; 14.1 vs. 3.2 months, p < 0.001), distant metastatic-free survival (DMFS; not reached vs. 25.8 months, p = 0.006), and overall survival (OS; 56.0 vs. 26.7 months, p = 0.0004). Sarcoma responders had a significantly longer IPFS (13.0 vs. 2.7 months, p < 0.0001), but no significant distant metastatic or OS advantage. Over a median follow-up of 19.3 months, sarcoma patients had an overall limb salvage rate of 68.4%.

conclusionILI is a well-tolerated procedure for patients with locally advanced melanoma, sarcoma, and other cutaneous malignancies. ILI responders had a significantly longer time to IPFS, while melanoma responders also had a DMFS and OS advantage.

Indexed as

Chemotherapy, Cancer, Regional PerfusionLimb SalvageAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Merkel CellCarcinoma, Squamous CellExtremitiesFemaleFollow-Up StudiesHumansMaleMelanomaMiddle AgedPrognosis

Identifiers

PMID29019175
PMCPMC7771340
OpenAlexW2761169565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.